Rilpivirine patent expiry?

Rilpivirine (used in HIV treatment; e.g., as rilpivirine hydrochloride in EDURANT® and components of some combination products) has had multiple patent and exclusivity events over time. The exact “patent expiry” date depends on which patent family, which country/region (US, EU, UK, etc.), and whether you mean the active ingredient patent vs. method-of-use/composition vs. data exclusivity.

Key takeaway

• Many rilpivirine-originator patents have already moved toward expiry in the US/EU, but not all jurisdictions/patent families expire on the same day, and there can also be secondary patents and regulatory exclusivities that affect when generics can launch.

What I need from you to give a precise expiry date

1. Country/region (e.g., US, EU/EP, UK, Canada, etc.)
2. Are you asking about:
   • Active ingredient (compound) patent expiry, or
   • Brand exclusivity / regulatory exclusivity, or
   • Generic launch date (which may be later/earlier depending on litigation/ANDA timing)
3. If you know it: the brand/product you care about (EDURANT®, Juluca®, Complera®, etc.)

If you tell me the region (e.g., US vs EU) and the brand, I can narrow it down to the relevant patent/exclusivity timeline and give you the most accurate expiry estimate.